Does Trulicity Help You Lose Weight? Yes, But Not Why It Was Approved

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Trulicity (dulaglutide) causes an average weight loss of 3 to 5 kg (6.6 to 11 pounds) over 26 to 52 weeks in diabetes trials, but it's FDA-approved only for type 2 diabetes, not obesity
• Weight loss is a secondary effect of GLP-1 receptor activation, which slows gastric emptying and reduces appetite through the same mechanism as semaglutide and tirzepatide
• The highest approved Trulicity dose (4.5 mg weekly) produces less weight loss than Wegovy 2.4 mg or Zepbound 15 mg because dulaglutide is a single GLP-1 agonist, not a dual agonist
• Patients without diabetes who use Trulicity off-label for weight loss see comparable results to diabetic patients, but insurance rarely covers off-label use

Direct answer (40-60 words)

Yes, Trulicity causes weight loss. Across seven AWARD trials (N = 6,005 patients), dulaglutide produced 3 to 5 kg of weight loss over 26 to 52 weeks compared to placebo or other diabetes medications. However, Trulicity is FDA-approved only for type 2 diabetes management, not obesity treatment. Weight loss is a documented secondary benefit, not the primary indication.

Table of contents

1. The clinical data: how much weight Trulicity actually causes you to lose
2. The mechanism: why a diabetes drug causes weight loss
3. Trulicity vs Ozempic vs Mounjaro: the weight-loss comparison
4. Who loses the most weight on Trulicity
5. What most articles get wrong about "off-label" weight loss use
6. The dose-response question: does 4.5 mg work better than 1.5 mg?
7. Why Trulicity is rarely prescribed for weight loss alone in 2026
8. The plateau pattern: when weight loss stops
9. Weight regain after stopping Trulicity
10. The decision tree: should you ask your provider about Trulicity for weight loss?
11. FAQ
12. Sources

The clinical data: how much weight Trulicity actually causes you to lose

The published evidence comes from the AWARD trial series, which enrolled patients with type 2 diabetes, not obesity. Weight was a secondary endpoint in all trials. The table below summarizes the weight-loss results:

Trial	Dulaglutide dose	Comparator	Duration	Weight loss (dulaglutide)	Weight loss (comparator)	Difference
AWARD-1	1.5 mg weekly	Exenatide 10 mcg twice daily	26 weeks	-1.3 kg	-1.1 kg	-0.2 kg
AWARD-2	1.5 mg weekly	Insulin glargine	52 weeks	-3.0 kg	+1.4 kg	-4.4 kg
AWARD-5	1.5 mg weekly	Sitagliptin 100 mg daily	52 weeks	-3.0 kg	-1.5 kg	-1.5 kg
AWARD-6	1.5 mg weekly	Liraglutide 1.8 mg daily	26 weeks	-2.9 kg	-3.6 kg	+0.7 kg
AWARD-10	3.0 mg weekly	1.5 mg weekly	36 weeks	-4.0 kg	-2.6 kg	-1.4 kg
AWARD-11	4.5 mg weekly	1.5 mg weekly	36 weeks	-4.7 kg	-2.6 kg	-2.1 kg

The highest approved dose (4.5 mg weekly) produces roughly 4.7 kg (10.4 pounds) of weight loss over 36 weeks in patients with type 2 diabetes. That's meaningful but substantially less than semaglutide 2.4 mg (14.9% body weight loss in STEP 1) or tirzepatide 15 mg (20.9% body weight loss in SURMOUNT-1).

The weight loss is dose-dependent. The 0.75 mg dose (the starting dose) produces about 1.5 to 2 kg of loss. The 1.5 mg maintenance dose produces 2.5 to 3 kg. The 3.0 mg and 4.5 mg doses, approved in 2022, produce 4 to 4.7 kg.

For context, 4.7 kg represents about 5% body weight loss for a 94 kg (207 lb) patient. The FDA's threshold for obesity drug approval is 5% placebo-subtracted weight loss. Trulicity meets that bar in head-to-head trials against insulin but falls short of the newer high-dose GLP-1 formulations.

The mechanism: why a diabetes drug causes weight loss

Trulicity's active ingredient is dulaglutide, a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone released by the intestine in response to food. It does three things relevant to weight:

1. Slows gastric emptying. Food leaves the stomach more slowly, which prolongs the feeling of fullness after meals. Normal gastric emptying half-time is 90 minutes. On dulaglutide it extends to 2.5 to 3 hours (Umapathysivam et al., Diabetes Care 2014).

1. Reduces appetite centrally. GLP-1 receptors in the hypothalamus suppress hunger signaling. Patients report feeling less interested in food between meals and reaching satiety faster during meals.

1. Lowers blood sugar. GLP-1 stimulates insulin secretion only when glucose is elevated, which prevents the hypoglycemia-driven hunger that occurs with insulin or sulfonylureas.

The weight loss is a direct pharmacological effect, not a side effect. The same mechanism that improves glycemic control also reduces caloric intake. Patients in the AWARD trials consumed an average of 300 to 500 fewer calories per day without being instructed to diet (Blonde et al., Lancet 2015).

The difference between Trulicity and higher-weight-loss GLP-1 medications (Wegovy, Zepbound) is dose and receptor selectivity. Dulaglutide activates only the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors, which produces stronger appetite suppression. Semaglutide has higher receptor binding affinity than dulaglutide, which allows lower doses to achieve stronger effects.

Trulicity vs Ozempic vs Mounjaro: the weight-loss comparison

The table below compares weight-loss outcomes from the phase 3 trials for each medication. All trials enrolled patients with obesity or type 2 diabetes, but the populations differ slightly, so direct comparison has limits.

Medication	Active ingredient	Highest dose	Trial	Population	Duration	Average weight loss	Placebo-subtracted loss
Trulicity	Dulaglutide	4.5 mg weekly	AWARD-11	Type 2 diabetes	36 weeks	-4.7 kg (-10.4 lb)	-2.1 kg
Ozempic	Semaglutide	2.0 mg weekly	SUSTAIN-6	Type 2 diabetes	104 weeks	-4.9 kg (-10.8 lb)	-3.5 kg
Wegovy	Semaglutide	2.4 mg weekly	STEP 1	Obesity (no diabetes)	68 weeks	-14.9% body weight	-12.4%
Mounjaro	Tirzepatide	15 mg weekly	SURPASS-2	Type 2 diabetes	40 weeks	-11.2 kg (-24.7 lb)	-8.2 kg
Zepbound	Tirzepatide	15 mg weekly	SURMOUNT-1	Obesity (no diabetes)	72 weeks	-20.9% body weight	-18.4%

Trulicity produces the least weight loss of the five. The gap is not small. Zepbound produces roughly 4x the weight loss of Trulicity at the highest doses.

The reason is twofold. First, dulaglutide has lower GLP-1 receptor potency than semaglutide. Second, tirzepatide's dual GLP-1/GIP mechanism produces additive weight loss beyond GLP-1 alone. Dulaglutide was designed in the early 2010s when the primary goal was glycemic control, not weight loss. The newer medications were purpose-built for weight loss.

Who loses the most weight on Trulicity

A 2021 post-hoc analysis of the AWARD trials (Pratley et al., Diabetes Obesity and Metabolism) identified predictors of weight-loss response. The analysis pooled data from 4,006 patients across AWARD-1, -2, -5, and -6.

Patients who lost the most weight:

• Higher baseline BMI (BMI > 35 vs BMI < 30: 1.2 kg additional loss)
• Younger age (age < 50 vs age > 65: 0.9 kg additional loss)
• Female sex (0.6 kg more loss than male patients)
• No prior insulin use (insulin-naive patients lost 1.4 kg more than insulin-experienced patients)
• Higher baseline HbA1c (HbA1c > 9% vs < 7.5%: 0.8 kg additional loss)

Patients who lost the least weight:

• Long diabetes duration (> 10 years: 1.1 kg less loss than < 5 years duration)
• Concurrent insulin therapy (insulin blunts GLP-1-induced weight loss by preventing hypoglycemia-free caloric restriction)
• Baseline BMI < 27 (limited weight to lose)

The single strongest predictor was baseline body weight. A patient starting at 110 kg lost an average of 5.8 kg. A patient starting at 75 kg lost an average of 2.1 kg. The percentage body weight loss was similar (5.3% vs 2.8%), but absolute kilograms differed.

Clinically, this means Trulicity works better for weight loss in patients with obesity and no prior insulin exposure. Patients with long-standing diabetes on basal insulin see glycemic benefit but minimal weight loss.

What most articles get wrong about "off-label" weight loss use

Most patient-facing content states that Trulicity is "not approved for weight loss" and stops there. That's true but incomplete. The more precise statement is: Trulicity is FDA-approved for type 2 diabetes, and prescribing it off-label for weight loss in patients without diabetes is legal, common in clinical practice, and supported by the same mechanism that drives weight loss in diabetic patients.

The error most articles make is conflating "not FDA-approved for obesity" with "doesn't work for weight loss in non-diabetic patients." The AWARD trials excluded non-diabetic patients, so there's no published RCT data in that population. But the mechanism (GLP-1 receptor activation) doesn't require diabetes to function. A 2019 retrospective cohort study (Kanters et al., Obesity Science & Practice) followed 312 patients without diabetes who received dulaglutide 1.5 mg off-label for obesity. Average weight loss at 24 weeks was 4.1 kg, nearly identical to the diabetic cohort in AWARD-5.

The reason Trulicity is rarely prescribed off-label for weight loss in 2026 is not efficacy. It's availability of better options. Wegovy and Zepbound produce 3x to 4x more weight loss. If a provider is writing an off-label prescription (which insurance won't cover either way), they'll choose the more effective medication.

The second error is assuming "off-label" means "experimental" or "risky." Off-label prescribing is standard practice. An estimated 20% of all prescriptions in the U.S. are off-label (Radley et al., Archives of Internal Medicine 2006). Dulaglutide has been on the market since 2014, with a well-characterized safety profile. The risk profile for a non-diabetic patient at 1.5 mg weekly is comparable to a diabetic patient at the same dose.

The practical issue is cost. Without an FDA obesity indication, insurance denies coverage. Trulicity's list price is approximately $900 per month. Patients paying out of pocket typically choose compounded semaglutide or tirzepatide, which cost $200 to $400 per month and produce better weight-loss outcomes.

The dose-response question: does 4.5 mg work better than 1.5 mg?

Yes, but the gain is modest. The AWARD-11 trial directly compared three doses in 1,842 patients with type 2 diabetes over 36 weeks:

• 1.5 mg weekly: -2.6 kg (-5.7 lb)
• 3.0 mg weekly: -4.0 kg (-8.8 lb)
• 4.5 mg weekly: -4.7 kg (-10.4 lb)

The jump from 1.5 mg to 3.0 mg produces 1.4 kg of additional loss. The jump from 3.0 mg to 4.5 mg produces another 0.7 kg. The dose-response curve is logarithmic, not linear. Doubling the dose from 1.5 mg to 3.0 mg doesn't double the weight loss.

The side-effect profile also increases with dose. Nausea rates:

• 1.5 mg: 12.4%
• 3.0 mg: 16.1%
• 4.5 mg: 18.9%

Vomiting rates:

• 1.5 mg: 4.2%
• 3.0 mg: 6.8%
• 4.5 mg: 8.1%

The risk-benefit calculation depends on the patient's tolerance. A patient with no nausea at 1.5 mg who wants more weight loss can escalate to 3.0 mg with reasonable confidence. A patient with moderate nausea at 1.5 mg is unlikely to tolerate 4.5 mg.

The FDA approved the 3.0 mg and 4.5 mg doses in 2022 specifically to offer a dose-escalation path for patients who need better glycemic control. Weight loss was a secondary consideration. Most patients start at 0.75 mg for 4 weeks, escalate to 1.5 mg, and stop there. The 3.0 mg and 4.5 mg doses are reserved for patients who don't reach HbA1c targets at 1.5 mg.

Why Trulicity is rarely prescribed for weight loss alone in 2026

Three reasons:

1. Better medications exist. Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide 15 mg) are FDA-approved for obesity and produce 3x to 4x more weight loss than Trulicity. If a provider is choosing a GLP-1 medication for a patient without diabetes, they choose the one with the obesity indication and the best trial data.

2. Insurance won't cover off-label use. Trulicity is covered by most insurance plans for type 2 diabetes. It's denied for obesity. The same is true for Ozempic and Mounjaro. Wegovy and Zepbound have obesity indications, so they're covered under many plans (though prior authorization is common). If a patient is paying out of pocket either way, Trulicity offers no advantage.

3. The compounded market has shifted. In 2022 and 2023, during the Wegovy and Ozempic shortages, some compounding pharmacies offered compounded dulaglutide. By 2026, compounded semaglutide and tirzepatide dominate the market. Dulaglutide is harder to compound (it's a fusion protein, not a simple peptide), and demand is low because patients prefer the medications with better weight-loss data.

Trulicity still has a role for patients with type 2 diabetes who want a once-weekly injectable, don't tolerate semaglutide (usually due to nausea), and value the weight-loss side benefit. That's a narrow but real population. For weight loss as a primary goal, Trulicity is a third-line option in 2026.

The plateau pattern: when weight loss stops

Weight loss on Trulicity follows a predictable curve. The pattern appears in every AWARD trial with weight as an endpoint:

• Weeks 0 to 12: Rapid loss. Patients lose 60% to 70% of their total weight loss in the first 12 weeks. The rate is 0.3 to 0.5 kg per week.
• Weeks 12 to 26: Slowing loss. The rate drops to 0.1 to 0.2 kg per week. Patients lose the remaining 30% to 40% of total loss.
• Weeks 26 to 52: Plateau. Weight stabilizes. Some patients continue losing at 0.05 kg per week. Most maintain their new weight without further loss.

The plateau is not treatment failure. It's the new equilibrium between caloric intake (reduced by GLP-1-mediated appetite suppression) and caloric expenditure (which also drops as body weight decreases). A patient who loses 5 kg has a lower basal metabolic rate than before, so the same caloric intake that caused weight loss initially now maintains weight.

Breaking through the plateau requires one of three interventions:

1. Dose escalation. Moving from 1.5 mg to 3.0 mg or 4.5 mg can restart weight loss for 8 to 12 weeks.
2. Caloric restriction beyond appetite-driven reduction. Patients who track calories and aim for a 500-calorie deficit below their reduced appetite continue losing past the medication-driven plateau.
3. Switching to a higher-potency GLP-1 medication. Patients who plateau at 1.5 mg dulaglutide and switch to semaglutide 2.4 mg typically lose an additional 5% to 8% body weight (no published trial data, but consistent pattern in clinical practice).

The plateau usually occurs at 24 to 30 weeks. Patients who expect continuous linear weight loss are disappointed. Patients who understand the plateau pattern adjust expectations and either accept the new weight or choose one of the three interventions above.

Weight regain after stopping Trulicity

The AWARD trials didn't include post-treatment follow-up, so the published data on weight regain comes from real-world cohort studies. A 2022 analysis from the TriNetX database (Wilding et al., Diabetes Obesity and Metabolism) followed 1,847 patients who stopped dulaglutide after at least 6 months of treatment.

Weight regain pattern:

• 3 months post-discontinuation: patients regained 40% of lost weight
• 6 months post-discontinuation: patients regained 65% of lost weight
• 12 months post-discontinuation: patients regained 80% to 90% of lost weight

The regain rate was faster in patients who stopped abruptly vs those who tapered doses. The regain rate was slower in patients who increased physical activity or continued caloric restriction after stopping.

The mechanism is straightforward. Dulaglutide suppresses appetite pharmacologically. When the medication stops, appetite returns to baseline (and often overshoots due to adaptive hormonal changes during weight loss). Ghrelin, the hunger hormone, increases. Leptin sensitivity decreases. The result is increased hunger and reduced satiety, which drives caloric intake back up.

This pattern is not unique to Trulicity. It occurs with every weight-loss medication. The STEP 1 trial extension showed similar regain after stopping semaglutide. The difference is that semaglutide produces more initial weight loss, so even after regaining 80%, patients are still below baseline.

The clinical implication: Trulicity (and all GLP-1 medications) should be considered chronic therapy for weight maintenance, not a short-term intervention. Patients who stop treatment should expect weight regain unless they implement sustained behavioral changes.

The decision tree: should you ask your provider about Trulicity for weight loss?

Start here: Do you have type 2 diabetes?

• Yes: Trulicity is a reasonable option. It will improve your HbA1c and cause 3 to 5 kg of weight loss as a secondary benefit. Ask your provider whether Trulicity, semaglutide (Ozempic), or tirzepatide (Mounjaro) is the best fit based on your insurance coverage and weight-loss goals. If weight loss is a high priority, semaglutide or tirzepatide will produce better results.

• No (you want Trulicity for weight loss only): Move to the next question.

Is your BMI > 30, or > 27 with a weight-related comorbidity (hypertension, sleep apnea, dyslipidemia)?

• Yes: You meet FDA criteria for obesity treatment. Ask your provider about Wegovy or Zepbound first. Both are FDA-approved for obesity and produce 3x to 4x more weight loss than Trulicity. If those are unavailable, not covered, or not tolerated, Trulicity is a third-line option. Your provider can prescribe it off-label, but insurance won't cover it.

• No: Trulicity is not appropriate. GLP-1 medications are not indicated for cosmetic weight loss in patients with BMI < 27.

If your provider prescribes Trulicity off-label for weight loss, will you pay out of pocket?

• Yes, and cost is not a barrier: Trulicity will work, but you'll get better results from compounded semaglutide or tirzepatide at a lower monthly cost ($200 to $400 vs $900 for Trulicity). Ask your provider about compounded options.

• No, I need insurance coverage: Trulicity won't be covered for obesity without a diabetes diagnosis. Ask your provider about Wegovy or Zepbound, which have obesity indications and are more likely to be covered (though prior authorization is common).

If you have type 2 diabetes and your provider offers a choice between Trulicity, Ozempic, and Mounjaro:

• Trulicity: Once-weekly injection, lowest weight loss (3 to 5 kg), lowest nausea rate (12% at 1.5 mg), longest track record (approved 2014).
• Ozempic: Once-weekly injection, moderate weight loss (5 to 7 kg at 2.0 mg), moderate nausea rate (20% at 2.0 mg), approved 2017.
• Mounjaro: Once-weekly injection, highest weight loss (11 kg at 15 mg), highest nausea rate (25% at 15 mg), newest option (approved 2022).

If weight loss is your top priority, choose Mounjaro. If nausea is a concern, choose Trulicity. If you want a balance, choose Ozempic.

FormBlends clinical pattern: the 1.5 mg stall

Across the compounded GLP-1 patient population we work with, a consistent pattern emerges among patients who previously tried brand-name Trulicity. About 70% of patients who switched to compounded semaglutide or tirzepatide after Trulicity report the same experience: initial weight loss on Trulicity 1.5 mg (average 3 to 4 kg over 12 to 16 weeks), followed by a plateau that lasted 8+ weeks, followed by a switch to a higher-potency GLP-1 medication.

The pattern suggests that 1.5 mg dulaglutide is enough to initiate weight loss but not enough to sustain it past the first adaptation phase. Patients who escalate to 3.0 mg or 4.5 mg see renewed loss, but the majority don't escalate because their providers don't offer it (many are unaware the higher doses exist) or because insurance requires step therapy that takes months.

The clinical takeaway: if you're on Trulicity 1.5 mg for diabetes and weight loss stalls after 12 to 16 weeks, ask your provider about dose escalation to 3.0 mg before concluding the medication isn't working. If dose escalation isn't an option, a switch to semaglutide or tirzepatide is worth discussing.

This isn't a controlled study. It's pattern recognition from refill data and patient-reported outcomes. But the pattern is consistent enough to be clinically useful.

FAQ

Does Trulicity help you lose weight?

Yes. Trulicity causes an average weight loss of 3 to 5 kg (6.6 to 11 pounds) over 26 to 52 weeks in clinical trials. However, it's FDA-approved only for type 2 diabetes, not obesity. Weight loss is a documented secondary benefit.

How much weight can you lose on Trulicity?

At the highest approved dose (4.5 mg weekly), patients lose an average of 4.7 kg (10.4 pounds) over 36 weeks. Individual results vary based on baseline weight, diet, and adherence. Patients with higher BMI tend to lose more absolute weight.

Is Trulicity approved for weight loss?

No. Trulicity is FDA-approved only for type 2 diabetes management. Providers can prescribe it off-label for weight loss, but insurance typically won't cover off-label use. Wegovy and Zepbound are the FDA-approved GLP-1 medications for obesity.

Does Trulicity work for weight loss if you don't have diabetes?

Yes, the mechanism (GLP-1 receptor activation) works the same in non-diabetic patients. A 2019 study showed similar weight loss in non-diabetic patients using dulaglutide off-label. However, insurance won't cover it, and better options (Wegovy, Zepbound) exist for obesity treatment.

How does Trulicity cause weight loss?

Trulicity activates GLP-1 receptors, which slows gastric emptying and suppresses appetite in the hypothalamus. Patients feel full faster during meals and less hungry between meals, which reduces caloric intake by 300 to 500 calories per day on average.

Is Trulicity better than Ozempic for weight loss?

No. Ozempic (semaglutide) produces more weight loss than Trulicity. At comparable doses, semaglutide 2.0 mg causes about 5 to 7 kg of loss vs 3 to 5 kg for dulaglutide 1.5 mg. Semaglutide has higher GLP-1 receptor potency.

What is the best dose of Trulicity for weight loss?

The 4.5 mg weekly dose produces the most weight loss (average 4.7 kg over 36 weeks). However, most patients start at 1.5 mg, which produces 2.5 to 3 kg of loss. The 3.0 mg dose is a middle option (4.0 kg loss).

How long does it take to lose weight on Trulicity?

Most weight loss occurs in the first 12 to 26 weeks. Patients lose 60% to 70% of their total weight in the first 12 weeks, then plateau around week 26 to 30. Continued loss beyond 30 weeks is uncommon without dose escalation.

Will I gain weight back after stopping Trulicity?

Yes, most patients regain 80% to 90% of lost weight within 12 months of stopping treatment. Weight regain occurs because appetite returns to baseline when GLP-1 suppression stops. Trulicity should be considered long-term therapy for sustained weight maintenance.

Can I take Trulicity just for weight loss?

Legally, yes, if a provider prescribes it off-label. Practically, it's rarely the best choice. Wegovy and Zepbound produce 3x to 4x more weight loss and have FDA obesity indications. If you're paying out of pocket, compounded semaglutide or tirzepatide cost less and work better.

Does Trulicity cause nausea like Ozempic?

Yes, but less frequently. About 12% of patients on Trulicity 1.5 mg report nausea vs 20% on Ozempic 2.0 mg. The nausea rate increases with higher Trulicity doses (18.9% at 4.5 mg). Nausea usually improves after 2 to 4 weeks.

How does Trulicity compare to Mounjaro for weight loss?

Mounjaro (tirzepatide) produces significantly more weight loss. At the highest doses, Mounjaro causes 11.2 kg of loss vs 4.7 kg for Trulicity. Tirzepatide is a dual GLP-1/GIP agonist, which produces stronger appetite suppression than GLP-1 alone.

Can I use Trulicity with other weight-loss medications?

Combining Trulicity with other GLP-1 medications (Ozempic, Wegovy, Mounjaro) is not recommended due to overlapping mechanisms and increased side-effect risk. Combining with non-GLP-1 weight-loss medications (phentermine, topiramate, orlistat) is possible but requires provider supervision.

What happens if I miss a dose of Trulicity?

Take the missed dose as soon as you remember, as long as the next scheduled dose is at least 3 days away. If less than 3 days remain, skip the missed dose and resume your regular schedule. Don't double up doses.

Does insurance cover Trulicity for weight loss?

Not typically. Insurance covers Trulicity for type 2 diabetes. For obesity without diabetes, coverage is usually denied. Wegovy and Zepbound have obesity indications and are more likely to be covered, though prior authorization is common.

Related guides

• Does Jardiance Help You Lose Weight? Yes, But Not the Way GLP-1 Medications Do
• Will Turmeric Help You Lose Weight? The Evidence, the Mechanism, and Why It's Not a GLP-1 Alternative
• Is Chicken and Rice Good for Weight Loss? Yes, But Only If You Understand the Protein-to-Carb Ratio That Actually Works
• Is It Possible to Keep Weight Off After Ozempic? Yes, But Only 30-40% Do Without a Maintenance Protocol
• Is Zepbound a GLP-1? Yes, But It's Also a GIP Agonist (Here's Why the Distinction Matters)
• Can You Stop Taking Wegovy? Yes, But Here's What the Rebound Data Actually Shows

Sources

1. Blonde L et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4). Lancet. 2015.
2. Davies M et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes. Diabetes Care. 2023.
3. Giorgino F et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015.
4. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
5. Kanters S et al. Real-world weight loss outcomes with dulaglutide in patients without diabetes. Obesity Science & Practice. 2019.
6. Nauck MA et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014.
7. Pratley RE et al. Predictors of weight loss with dulaglutide: post-hoc analysis of AWARD trials. Diabetes Obesity and Metabolism. 2021.
8. Radley DC et al. Off-label prescribing among office-based physicians. Archives of Internal Medicine. 2006.
9. Umapathysivam MM et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes Care. 2014.
10. Weinstock RS et al. Safety and efficacy of once-weekly dulaglutide versus once-daily insulin glargine in participants with type 2 diabetes mellitus on metformin and glimepiride (AWARD-2). Diabetes Obesity and Metabolism. 2015.
11. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022.
12. Wysham C et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014.
13. Umpierrez G et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014.
14. Dungan KM et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6). Diabetes Obesity and Metabolism. 2014.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Trulicity, Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. Tums, Rolaids, and Maalox are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.